To receive the Femtech World newsletter, sign up here.
News
California entrepreneurs launch retreat to ‘demystify’ postpartum recovery
The retreat aims to fill the critical care gap following childbirth and promote bonding
Two California-based entrepreneurs have launched a postnatal retreat to “demystify” postpartum recovery.
Esther Park and Christina DeJesus, founders of Ahma & Co, aim to raise the standard of postpartum care in the US, using a successful care model from South Korea.
Their initiative, a postnatal retreat providing holistic postpartum recovery and newborn care support for mothers, is set to welcome new mothers from March 15 at the Waldorf Astoria Monarch Beach in Orange County, California.
The retreat is the first of its kind in Orange County and aims to fill the critical care gap following childbirth and promote bonding.
According to Ahma & Co, the service is designed to support mothers and parents by “demystifying” postpartum recovery and newborn care and relieving the burdens at home, such as cooking and cleaning.
The project features a range of professionals, including doulas, newborn care specialists, lactation educators and therapists, with the aim to provide round-the-clock support.
“Mothers often feel the pressure to prioritise the care of their newborn, with their recovery needs becoming secondary; they also often spend long periods in isolation with little support or guidance, which has long-term implications to their physical and mental health, and therefore those of their families,” explained Park, Ahma & Co CEO.

Co-founders Park and DeJesus aims to enhance postpartum care with quality support and partner-inclusive education
“We’re proud to offer a space where maternal love and self love don’t need to be mutually exclusive.”
DeJesus, Ahma & Co COO, said: “After working with families in the hospital, joining Esther was a natural step in addressing the horrifying maternal health outcomes in the US.
“Together, we’re committed to meeting the stark care gap in the crucial early weeks of postpartum, ensuring that mothers and families are set up for success in the long term.”
The US faces daunting maternal health statistics, with a maternal death rate three times higher than other developed countries, 20 per cent of mothers experiencing postpartum-related mental health conditions and 60 per cent stopping breastfeeding earlier than planned.
“High-quality, comprehensive postpartum care should not be considered a nice-to-have or an afterthought,” said the Ahma & Co founders.
“It should be a necessity that all mothers and families deserve.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






